Chris Bredeson profile picture

Contact Information

Chris Bredeson, MD MSc FRCPC
(613) 737-8899 ext 73904

Chris Bredeson

Senior Clinician Investigator, Clinical Epidemiology Program
Ottawa Hospital Research Institute
Head, Malignant Hematology & Stem Cell Transplantation
The Ottawa Hospital

Research Interests

Dr. Bredeson’s research interests remain primarily in clinical research related to improving results of allogeneic stem cell transplantation. He has a growing interest in the issues related to health care delivery and sustainability.  He participates in National and International observation research studies and with local colleagues on trials of novel therapies for poor risk patient populations.

Brief Biography

Dr. Christopher Bredeson received a medical degree (cum laude) from the University of Ottawa. His post-doctorate training included an internship and residency in internal medicine at The Ottawa Hospital, as well as a residency in clinical hematology and a fellowship in the Leukemia/Bone Marrow Transplant Program at the University of British Columbia in Vancouver. He holds a Masters degree in Clinical Epidemiology also from the University of Ottawa.

Dr. Bredeson returned to Ottawa in 2011 after a decade at the Medical College of Wisconsin where he was a Scientific Director at the Center for International Blood and Marrow Transplant Research. While there he participated in the establishment of the NIH funded Blood and Marrow Transplant Clinical Trials Network and designed and ran several of their early trials.  Dr. Bredeson returned to Ottawa to run the Malignant Hematology and Stem Cell Transplantation Programme at The Ottawa Hospital. 

Dr Bredeson is a Professor in the Faculty of Medicine and Senior Scientist at the Ottawa Hospital Research Institute.

Selected Publications

1. Sanders S, Bredeson C, Pringle CE, Martin L, Allan D, Bence-Bruckler I,Hamelin L, Hopkins HS, Sabloff M, Sheppard D, Tay J, Huebsch L, Atkins HL. Autologous Stem Cell Transplantation for Stiff Person Syndrome: Two Cases From the Ottawa Blood and Marrow Transplant Program. JAMA Neurol. 2014 Aug 25.  

2. Bredeson C, LeRademacher J, Kato K, Dipersio JF, Agura E, Devine SM, Appelbaum FR, Tomblyn MR, Laport GG, Zhu X, McCarthy PL, Ho VT, Cooke KR, Armstrong E, Smith A, Rizzo JD, Burkart JM, Pasquini MC. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood. 2013 Dec 5;122(24):3871-8.

3. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer DL; Blood and Marrow Transplant Clinical Trials Network. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012 Oct 18;367(16):1487-96.

4. Sheppard D, Bredeson C, Allan D, Tay J. Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2012 Aug;18(8):1191-203.

5. Bredeson CN, Zhang MJ, Agovi MA, Bacigalupo A, Bahlis NJ, Ballen K, Brown C, Chaudhry MA, Horowitz MM, Kurian S, Quinlan D, Muehlenbien CE, Russell JA, Savoie L, Rizzo JD, Stewart DA. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant. 2008 Sep;14(9):993-1003.

Diseases, conditions and populations of interest

Research and clinical approaches